JP2016512507A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512507A5 JP2016512507A5 JP2016500947A JP2016500947A JP2016512507A5 JP 2016512507 A5 JP2016512507 A5 JP 2016512507A5 JP 2016500947 A JP2016500947 A JP 2016500947A JP 2016500947 A JP2016500947 A JP 2016500947A JP 2016512507 A5 JP2016512507 A5 JP 2016512507A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- haloalkyl
- alkoxy
- hiv
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 32
- -1 homopiperidinyl Chemical group 0.000 claims 16
- 125000001188 haloalkyl group Chemical group 0.000 claims 15
- 125000003545 alkoxy group Chemical group 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000003302 alkenyloxy group Chemical group 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000001475 halogen functional group Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000004438 haloalkoxy group Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 8
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 239000002777 nucleoside Substances 0.000 claims 4
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 4
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 3
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 claims 2
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 230000034303 cell budding Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000002835 hiv fusion inhibitor Substances 0.000 claims 2
- 239000003084 hiv integrase inhibitor Substances 0.000 claims 2
- 239000004030 hiv protease inhibitor Substances 0.000 claims 2
- 230000035800 maturation Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- GZKRTCVCPGXHGH-SANMLTNESA-N (2S)-2-[2-[(4-fluorophenyl)methylsulfonylamino]-7-methyl-5-(4-methyl-4-prop-2-enoxypiperidin-1-yl)imidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC1=CC2=NC(NS(=O)(=O)CC3=CC=C(F)C=C3)=CN2C(N2CCC(C)(CC2)OCC=C)=C1[C@H](OC(C)(C)C)C(O)=O GZKRTCVCPGXHGH-SANMLTNESA-N 0.000 claims 1
- FYBJIBWIAPHLIY-VWLOTQADSA-N (2s)-2-[2-(3-benzyl-1,2,4-oxadiazol-5-yl)-5-(4,4-dimethylpiperidin-1-yl)-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3ON=C(CC=4C=CC=CC=4)N=3)=CN2C=1N1CCC(C)(C)CC1 FYBJIBWIAPHLIY-VWLOTQADSA-N 0.000 claims 1
- IEOMJICAAQPBAE-VWLOTQADSA-N (2s)-2-[2-(5-benzyl-1,3,4-oxadiazol-2-yl)-5-(4,4-dimethylpiperidin-1-yl)-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3OC(CC=4C=CC=CC=4)=NN=3)=CN2C=1N1CCC(C)(C)CC1 IEOMJICAAQPBAE-VWLOTQADSA-N 0.000 claims 1
- RSGJTTNSMQLVJM-VWLOTQADSA-N (2s)-2-[2-[4-chloro-5-[(4-fluorophenyl)methyl]-1h-imidazol-2-yl]-5-(4,4-dimethylpiperidin-1-yl)-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3NC(CC=4C=CC(F)=CC=4)=C(Cl)N=3)=CN2C=1N1CCC(C)(C)CC1 RSGJTTNSMQLVJM-VWLOTQADSA-N 0.000 claims 1
- QJWSOMMSNWFUOW-VWLOTQADSA-N (2s)-2-[5-(4,4-dimethylpiperidin-1-yl)-2-[(4-fluoro-3-methylphenyl)methylcarbamoyl]-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound C1=C(F)C(C)=CC(CNC(=O)C=2N=C3C=C(C)C([C@H](OC(C)(C)C)C(O)=O)=C(N4CCC(C)(C)CC4)N3C=2)=C1 QJWSOMMSNWFUOW-VWLOTQADSA-N 0.000 claims 1
- RQFSNOCDCIQHRC-SANMLTNESA-N (2s)-2-[5-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-oxazol-2-yl]-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3OC(CC=4C=CC(F)=CC=4)=CN=3)=CN2C=1N1CCC(C)(C)CC1 RQFSNOCDCIQHRC-SANMLTNESA-N 0.000 claims 1
- YFMDMKNSJXLNFI-SANMLTNESA-N (2s)-2-[5-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1,3-thiazol-2-yl]-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3SC(CC=4C=CC(F)=CC=4)=CN=3)=CN2C=1N1CCC(C)(C)CC1 YFMDMKNSJXLNFI-SANMLTNESA-N 0.000 claims 1
- YGEQFICGLUWQBM-SANMLTNESA-N (2s)-2-[5-(4,4-dimethylpiperidin-1-yl)-2-[5-[(4-fluorophenyl)methyl]-1h-imidazol-2-yl]-7-methylimidazo[1,2-a]pyridin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid Chemical compound CC(C)(C)O[C@H](C(O)=O)C=1C(C)=CC2=NC(C=3NC(CC=4C=CC(F)=CC=4)=CN=3)=CN2C=1N1CCC(C)(C)CC1 YGEQFICGLUWQBM-SANMLTNESA-N 0.000 claims 1
- 125000005336 allyloxy group Chemical group 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780179P | 2013-03-13 | 2013-03-13 | |
| US61/780,179 | 2013-03-13 | ||
| PCT/US2014/022354 WO2014164409A1 (en) | 2013-03-13 | 2014-03-10 | Inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512507A JP2016512507A (ja) | 2016-04-28 |
| JP2016512507A5 true JP2016512507A5 (enExample) | 2017-04-13 |
Family
ID=50771321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500947A Pending JP2016512507A (ja) | 2013-03-13 | 2014-03-10 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9655889B2 (enExample) |
| EP (1) | EP2970273B1 (enExample) |
| JP (1) | JP2016512507A (enExample) |
| CN (1) | CN105008358B (enExample) |
| ES (1) | ES2623777T3 (enExample) |
| WO (1) | WO2014164409A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9409922B2 (en) | 2014-02-18 | 2016-08-09 | Bristol-Myers Squibb Company | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication |
| ES2687322T3 (es) | 2014-02-19 | 2018-10-24 | VIIV Healthcare UK (No.5) Limited | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| US9975906B2 (en) | 2014-05-16 | 2018-05-22 | Shionogi & Co., Ltd. | Tricyclic heterocycle derivatives having HIV replication inhibitory effect |
| JP2017526748A (ja) * | 2014-08-27 | 2017-09-14 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤として使用するためのイミダゾ［１，２−ａ］ピリジン誘導体 |
| WO2016119700A1 (en) * | 2015-01-28 | 2016-08-04 | Jn Therapeutics | Substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof |
| CA2987384A1 (en) | 2015-05-29 | 2016-12-08 | Shionogi & Co., Ltd. | Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity |
| CN107820493A (zh) * | 2015-07-06 | 2018-03-20 | Viiv保健英国第五有限公司 | 作为人类免疫缺陷性病毒复制的抑制剂的吡啶‑3‑基乙酸衍生物 |
| KR20180025926A (ko) * | 2015-07-08 | 2018-03-09 | 비브 헬스케어 유케이 (넘버5) 리미티드 | 인간 면역결핍 바이러스 복제의 억제제로서의 피리딘-3-일 아세트산 유도체 |
| BR112018002681A2 (pt) * | 2015-08-10 | 2019-04-24 | Viiv Healthcare Uk No 5 Ltd | ?composto, composição, e, método para tratamento de infecção por hiv? |
| JP2023536893A (ja) * | 2020-08-14 | 2023-08-30 | シャンハイ フダン－チャンジャン バイオ－ファーマシューティカル カンパニー リミテッド | Ｊａｋ阻害剤の塩形、結晶及びその製造方法と使用 |
| CN113698342B (zh) * | 2021-10-29 | 2021-12-31 | 南京恒远科技开发有限公司 | 一种奥布替尼关键中间体杂环类化合物2,6-二氯烟酸的制备方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR910011852A (ko) * | 1989-12-04 | 1991-08-07 | 폴 디. 매튜카이티스 | 신경독 장해 치료용 이미다조[1,2-a]피리디닐알킬 화합물 |
| US6677352B1 (en) | 2001-09-26 | 2004-01-13 | Yamin Wang | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders |
| US20080234318A1 (en) * | 2005-08-31 | 2008-09-25 | Kristjan Gudmundsson | Chemical Compounds |
| US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| CA2705312C (en) | 2007-11-15 | 2013-06-25 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| US8377960B2 (en) | 2007-11-15 | 2013-02-19 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US8461180B2 (en) | 2007-11-16 | 2013-06-11 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| NZ585226A (en) | 2007-11-16 | 2012-08-31 | Gilead Sciences Inc | Inhibitors of human immunodeficiency virus replication |
| WO2010032195A1 (en) * | 2008-09-16 | 2010-03-25 | Csir | Imidazopyridines and imidazopyrimidines as hiv-i reverse transcriptase inhibitors |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| SG10201408512RA (en) | 2009-12-23 | 2015-02-27 | Univ Leuven Kath | Novel antiviral compounds |
| US9102614B2 (en) | 2010-07-02 | 2015-08-11 | Gilead Sciences, Inc. | Naphth-2-ylacetic acid derivatives to treat AIDS |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| EP2640729B1 (en) | 2010-11-15 | 2016-12-21 | VIIV Healthcare UK Limited | Inhibitors of hiv replication |
| NZ610315A (en) | 2010-11-15 | 2015-08-28 | Univ Leuven Kath | Antiviral condensed heterocyclic compounds |
| US8791108B2 (en) * | 2011-08-18 | 2014-07-29 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
-
2014
- 2014-03-10 ES ES14725559.0T patent/ES2623777T3/es active Active
- 2014-03-10 JP JP2016500947A patent/JP2016512507A/ja active Pending
- 2014-03-10 US US14/770,702 patent/US9655889B2/en not_active Expired - Fee Related
- 2014-03-10 CN CN201480013594.8A patent/CN105008358B/zh not_active Expired - Fee Related
- 2014-03-10 EP EP14725559.0A patent/EP2970273B1/en not_active Not-in-force
- 2014-03-10 WO PCT/US2014/022354 patent/WO2014164409A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512507A5 (enExample) | ||
| JP2016512558A5 (enExample) | ||
| JP2016512511A5 (enExample) | ||
| JP2017526748A5 (enExample) | ||
| JP2016506961A5 (enExample) | ||
| JP2015524841A5 (enExample) | ||
| RU2017107715A (ru) | Производные имидазо[1,2-a]пиридина для применения в качестве ингибиторов репликации вируса иммунодефицита человека | |
| JP2016528301A5 (enExample) | ||
| JP2016535795A5 (enExample) | ||
| JP2016516692A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| JP2016510038A5 (enExample) | ||
| JP2014526500A5 (enExample) | ||
| JP2013531031A5 (enExample) | ||
| RU2016142611A (ru) | Пролекарственные средства ингибиторов обратной транскриптазы вич | |
| JP2007519649A5 (enExample) | ||
| SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
| JP2015514808A5 (enExample) | ||
| JP2018522927A5 (enExample) | ||
| PH12022551359A1 (en) | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | |
| IL257240A (en) | History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication | |
| RU2015101102A (ru) | Гетероароматическое метильное производное циклического амина | |
| JP2014532754A5 (enExample) | ||
| RU2018106498A (ru) | Производные 5-(N-конденсированный трициклический арил-тетрагидроизохинолин-6-ил) пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| EA201170537A1 (ru) | Ингибиторы вич-интегразы |